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Mechthild Stoeckelhuber, MD, PhD,b Markus Pfirrmann, MSc,c Bruno Reichart, MD,d
Bernhard F. Becker, MD, PhD,e and Frank Christ, MD,a Munich, GermanyA healthy vascular endothelium is coated by the endothelial
glycocalyx. Its main constituents are transmembrane synde-
cans and bound heparan sulfates. In vivo the glycocalyx
binds plasma proteins, forming the endothelial surface layer,
which has a thickness of 500 to 1000 nm in microvessels.1
This large structure maintains the physiologic permeability
barrier and prevents leukocyte and platelet adhesion, thereby
mitigating inflammation and tissue edema.1,2
Very recently, we provided the first evidence for an acute
destruction of the endothelial glycocalyx in patients under-
going aortic surgery associated with ischemia reperfusion
injury.3 Avoiding cardiopulmonary bypass (CPB) and cardi-
oplegic arrest, including ischemia and reperfusion, should
presumably reduce shedding of the endothelial glycocalyx.
In the present study shedding of components of the endothe-
lial glycocalyx (heparan sulfate and syndecan-1) was inves-
tigated in patients undergoing coronary artery bypass
surgery with and without CPB.
CLINICAL SUMMARY
Patients referred for elective coronary artery bypass
surgery were prospectively randomized to on-pump conven-
tional coronary artery bypass (CCAB; n ¼ 15) or off-pump
coronary artery bypass (OPCAB; n¼ 15) surgery. Exclusion
criteria were former or combined cardiac procedures and re-
nal or hepatic dysfunction. Before surgical intervention,writ-
ten informed consent was obtained from each patient. The
study was approved by the ethics committee of our institu-
tion. CCAB andOPCABoperations were performed through
a median sternotomy. Mild hypothermia (32.0C) was used
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greater than 35.5C forOPCABsurgery. In patients undergo-
ing CCAB surgery, blood samples were taken before (T0)
and after (T1) induction of anesthesia and before surgical in-
cision, at the onset of CPB (T2), after removal of the aortic
crossclamp during completion of proximal anastomoses
(T3), 5minutes after CPB and at the beginning of surgical he-
mostasis (T4), and at skin closure (T5). The corresponding
time points for patients undergoingOPCAB surgerywere be-
fore (T0) and after (T1) induction of anesthesia and before
surgical incision, after the first application of the stabilizer
(T2), during completion of the proximal anastomoses with
the heart returned to its natural position (T3), at the start of
surgical hemostasis (T4), and at skin closure (T5). Plasma
blood samples were separated by means of centrifugation
and stored at80C until assay. Syndecan-1 and heparan sul-
fate concentrations were determined by means of ELISA.3
Saphenous veins left over after coronary arterybypassgraft-
ingwere obtained after the last proximal anastomosis was per-
formed and stored in 4% formaldehyde solution for 24 hours.
There were no differences regarding patients’ demo-
graphic data, duration of anesthesia, and operation. The clin-
ical course of all patients was uneventful. Figure 1 shows the
measured syndecan-1 and heparan sulfate concentrations in
the plasma of both groups. Anesthesia and initiation of sur-
gical intervention caused no significant changes. In CCAB
surgery the removal of the aortic crossclamp during reperfu-
sion of the heart and lungs led to significant median 2- and
4-fold increases in syndecan-1 and heparan sulfate concen-
trations, respectively. There were further increases 5minutes
after termination of CPB. Surprisingly, in patients undergo-
ing OPCAB surgery, there were also significant increases in
median syndecan-1 (4-fold) and heparan sulfate (2-fold)
concentrations during completion of the proximal anastomo-
ses. Syndecan-1 and heparan sulfate concentrations had re-
turned to basal levels by the end of the operation in both
the CCAB and OPCAB groups.
Light microscopic photographs showing the endothelial
glycocalyx of a human saphenous vein and its adventitial
vessels are depicted in Figure 2. Heparan sulfate and synde-
can-1 were detected at the luminal side of the endothelium.
DISCUSSION
The major finding of this study is that components of the
endothelial glycocalyx, syndecan-1 and heparan sulfate, are
released from the tissue and can be detected in the blood ofrdiovascular Surgery c Volume 138, Number 6 1445
Brief Research ReportsFIGURE 1. Individual and median values of syndecan 1 and heparan sulfate (upper and bottom panels, respectively) in arterial blood plasma of patients
undergoing conventional coronary artery bypass grafting (CCAB; left panels) and patients undergoing off pump coronary artery bypass grafting (OPCAB;
right panels) at different operative stages. Time points are as defined in the text. Syndecan 1 was determined directly by using an enzyme linked immuno
sorbent assay (Diaclone Research, Besancon, France). Heparan sulfate concentration was measured after pretreatment of plasma with Actinase E (Sigma, St
Louis, Mo) with a special enzyme linked immunosorbent assay kit (Seikagaku Corporation, Tokyo, Japan). *P<.05 versus T0 (Wilcoxon signed rank test;
P value was corrected according to the Bonferroni adjustment for testing 5 times).patients undergoing coronary artery bypass surgery. Such an
origin is suggested by the immunohistochemical localization
of both syndecan-1 and heparan sulfate at the luminal side of
the endothelium and by former experiments showing postis-
chemic reperfusion to coincide with multifold increases in
syndecan-1 and heparan sulfate levels and a visible destruc-
tion of the endothelial glycocalyx.3 Various animal models
showed this structure to be fundamentally involved in nu-1446 The Journal of Thoracic and Cardiovascular Smerous physiologic and pathophysiologic actions in the
circulatory system. Preservation of the glycocalyx should
maintain the endothelial permeability barrier and attenuate
blood cell vessel wall interactions, thereby mitigating in-
flammation and tissue edema.1,2
Because shedding of the glycocalyx was observed in the
present study in both the CCAB and OPCAB groups, ische-
mia reperfusion injury does not appear to be the sole triggerurgery c December 2009
Brief Research ReportsFIGURE 2. Immunostaining of a human saphenous vein and adventitial
artery with monoclonal antibody against heparan sulfate (A) and synde
can 1 (B). Sections (5 mm) were immunohistochemically stained with
monoclonal antibodies (heparan sulfate: Seikagaku Corporation, Tokyo,
Japan; syndecan 1: Biosource International, Camarillo, Calif). (Original
magnification: A, 23; B, 403. HS, Heparan sulfate; VL, vascular lumen;
S, syndecan 1.The Journal of Thoracic and Cfor disruption. During CCAB and OPCAB surgery, other
potential mechanisms, such as protease activation, increased
levels of proinflammatory cytokines, or oxidized lipopro-
teins, might account for destruction of the glycocalyx.2 In
addition, mechanical stress should cause liberation of atrial
natriuretic peptide. Shedding of the endothelial glycocalyx
caused by atrial natriuretic peptide was demonstrated in
guinea pig hearts.4 Given the importance of the glycocalyx,
further studies evaluating the mechanisms behind shedding
of the human glycocalyx are needed.
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